Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 6, Issue 5, 2004, Pages 363-366

  Bell, David S H ^a,b   Ovalle, F ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Combination therapy; Endogenous insulin; HbA1c; Metformin; Once daily; Rosiglitazone

Indexed keywords

C PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE;

ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DRUG DOSE REGIMEN; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 4444289371     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00357.x     Document Type: Article

References (12)

1. Bell DSH. Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes. Endocr Prac 2003; 9: 98-100.
2. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): Prospective Observational Study. BMJ 2000; 321: 405-412.
3. Khaw KT, Wareham N, Luben R et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
4. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic B-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
5. Ovalle F, Bell DSH. Effects of rosiglitazone vs insulin on the pancreatic beta cell function of subjects with type 2 diabetes mellitus. Diabetes 2003; 51 (Suppl. 1): A130.
6. Raskin P, Rappaport FB, Cole ST et al. Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with type 2 diabetes. Diabetologia 2000; 43: 278-284.
7. Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Prac 1997; 3: 281-283.
8. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in non-insulin dependent diabetes mellitus. J Clin Invest 1984; 73: 1532-1541.
9. Raskin P, Bode BW, Marks JB et al. Continuous subcutaneous insulin infusion and multiple daily insulin injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003; 26: 2598-2603.
10. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
11. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-1702; Erratum, JAMA 2000; 284: 1384.
12. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-134.